First Light Biosciences is now

First Light Diagnostics

First Light Diagnostics develops innovative diagnostic tests that enable rapid and accurate detection of pathogens that can cause life-threatening infections. Our antimicrobial susceptibility tests will help ensure that patients suffering from infection receive appropriate antibiotic treatment options in hours and not days compared to current practices. Leveraging our highly differentiated MultiPath™ technology, our products strive to save lives, lower healthcare costs, improve antibiotic stewardship, and prevent the spread of antibiotic drug-resistance.

Recent News & Upcoming Events

First Light Diagnostics Receives FDA Clearance for its Rapid B. anthracis Toxin Test on the MultiPath® Analyzer

Rapid, sensitive test for the early diagnosis of inhalation anthrax Chelmsford, MA (December 5, 2023) – First Light Diagnostics announced that the US Food and Drug Administration (FDA) has cleared its SensiTox® B. anthracis Toxin Test to be marketed in the U.S. B. anthracis, the agent that causes anthrax, is a top biodefense concern due…

Read More

First Light Diagnostics Receives FDA Clearance for its Rapid Clostridiodes difficile Test on the MultiPath® Analyzer

First FDA cleared product based on the Company’s proprietary MultiPath technology Chelmsford, MA (Jul 20, 2021) – First Light Diagnostics is developing and commercializing breakthrough automated diagnostic products for rapidly detecting infections and determining optimal treatment. The company announced today that the US Food and Drug Administration (FDA) has cleared its SensiTox™ C. difficile Toxin…

Read More

First Light Diagnostics Appoints Joanne Spadoro as Chief Executive Officer

Chelmsford, MA (May 5, 2021) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening antibiotic resistant infections, has named Joanne Spadoro, PhD as President and Chief Executive Officer (CEO). As the CEO of First Light Diagnostics, Dr. Spadoro will be responsible for leading the company through the…

Read More

First Light Diagnostics Receives Additional Funding from the Biomedical Advanced Research and Development Authority (BARDA)

Funding Supports Continued Development of the SensiTox™ B. anthracis Toxin Test Chelmsford, MA, October 27, 2020 – First Light Diagnostics, Inc., a developer of breakthrough automated products for the rapid diagnosis and treatment of life-threatening infections, today announced the authorization of a $4 million award from the Biomedical Advanced Research and Development Authority (BARDA), part…

Read More

First Light Diagnostics Names New Chief Financial Officer

Life Sciences Veteran Andrew Wilsack Joins Team Chelmsford, MA (May 28, 2020) – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, has appointed Andrew Wilsack as the company’s new CFO. “Andrew’s broad experience across disciplines will be an asset for us,” said David Macdonald,…

Read More
How First Light Diagnostics and their MultiPathTM Platform Can Help Patients Receive the Right Therapy at the Onset of Infection
Medical Practitioners Discuss the Causes and Impacts of Antibiotic Resistance and the Effect Rapid Results can Have to Address the Problem

What Sets Us Apart?

Our MultiPath technology is advancing the field of rapid diagnostics in several key areas:
Time to Result

Time to Result

The MultiPath technology outperforms current culture-based methods by providing pathogen identification results in 30 minutes and antimicrobial susceptibility test results in 4 hours…directly from patient sample.

Automation

Automation

The MultiPath analyzer is a fully automated “sample-to-answer” platform. By combining this level of automation with rapid tests, we can perform up to 40 antimicrobial susceptibility tests or 200 identification tests in a single 8-hour shift.

Versatility

Versatility

The MultiPath platform is unique in its ability to rapidly identify a broad range of pathogens, detect toxins and biomarkers with high sensitivity, and perform rapid phenotypic antimicrobial susceptibility testing.

Menu